NCT02596217View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Healthy
Interventions
DRUG

ABBV-066

SC injection

DRUG

ABBV-066

IV infusion

DRUG

Placebo

SC injection (stage 1)

DRUG

Placebo

IV infusion (stage 2)

Trial Locations (2)

Unknown

Boehringer Ingelheim Investigational Site, Tokyo, Sumida-ku

Boehringer Ingelheim Investigational Site, Busan

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY